Market Size (2016)
2016
$4.38B
Vertical: HealthcareBase Year: 201811 Sections
Market Size (2016)
2016
$4.38B
Projected (2025)
2025
$7.83B
CAGR (2016–2025)
6.7%
6.7%Key Players
109+
Influenza is an acute respiratory illness that affects the upper and lower respiratory tract and is caused by influenza virus, usually of type A, or B. Vaccination is the major public health measure for the prevention of influenza virus infection. Influenza vaccines are also known as flu shots or flu jabs. Various licensed seasonal influenza vaccines are available in the market, several of which have been prequalified by the WHO (World Health Organization) for purchase by the UN (United Nations) agencies. In addition, many vaccines against animal influenza A viruses are under the development phase.
The factors leading to the growth of the global influenza vaccines market are rising prevalence of influenza, increasing public & private initiatives for research & development of influenza vaccine, growing awareness about influenza vaccines, and increasing product launches & approvals. However, stringent regulatory policies and product recalls are the posing hurdles to the market growth on the global level. The increasing number of clinical trial candidates is likely to create opportunities for the growth of the market.
The Influenza Vaccines Market market is projected to grow at a CAGR of 6.7% from 2016 to 2025.
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Size (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansInfluenza vaccine is a vaccine that protects humans and animals from getting influenza. Influenza is an acute respiratory illness that affects the respiratory tract and is caused by the influenza virus, majorly of type A or B. Influenza can lead to serious health complications and may also lead to death. Influenza A viruses may cause pandemics that are characterized by rapid dissemination of new, virulent influenza A subtypes to which there is less or no existing immunity.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plansoverview
The research starts with the extensive procurement process of data/information and statistics from company annual reports, government websites, statistic agencies, and paid databases. This information creates a base for the study. This information also helps to define the scope and to narrow down the area for study for the market. This raw information is processed and analyzed to extract crisp data points that currently affect or are likely to affect the industry over the forecast period. After analyzing the information, a proprietary statistical tool is used for market estimation & forecast, which generates the quantitative figures/sizes of the market/sub-segments in the current scenario as well as for over the forecast period.
After estimating the market sizes & estimates, numbers are verified with the industry participants and key opinion leaders. The wide network of industry participants performs a value addition in the research and verify the numbers & estimates of the study. In the last stage of the research process, a final report is prepared, which is then published on different websites as well as distributed through various channels. The below figure contains the different stages of the whole research performed to produce the report.
DATA MINING
Data mining is one of the extensive stages of our research process. It involves the procurement of market data and related information through different verified & credible sources. This step helps to obtain the raw information about components in the industry and their deployment, the monetary process for different end-uses, the pool of market participants & the nature of the industry, and the scope of the study. The data mining stage comprises both primary as well as secondary sources of information.
SECONDARY RESEARCH
In the secondary research process, various sources are used to identify and gather industry trends and information for the research process. We at MRFR have access to some of the most diversified and extensive paid databases, which give us the most accurate data/information on market sizes, components, and pricing. Mentioned below is a detailed list of sources that have been used for this study. Please note that this list is not limited to the names as mentioned; we also access other data sources depending on the need.
Market Sizing & Revenue
Qualitative Information & Trends
Company Websites
· White Papers
· Magazines
· Company Websites
· Annual Reports
· Press Releases
· Investor Presentations
· Paid Databases
· Authenticated Directories
· Independent Studies
· Internal Audit Reports & Archives
· Government and Regulatory Published Material
· National Center for Biotechnology Information
· World Obesity Federation
· The Obesity Society
· ASMBS
· US Department of Health and Human Services
· Obesity Action Coalition
· National Kidney Foundation Inc.
· The Nemours Foundation
Annual Reports
Investor Presentations
Authenticated Directories
Hoover’s, Factiva, Bloomberg
PRIMARY RESEARCH
In the primary research process, in-depth primary interviews are conducted with the CXOs to understand the market share, customer base, pricing strategies, and other necessary information. Besides, in-depth primary interviews are conducted with the CXOs of companies, and others to validate the supply-side information. Moreover, various key industry participants from both the supply and demand side are interviewed to obtain qualitative and quantitative information on the market. In-depth interviews with key primary respondents, including industry professionals, subject matter experts (SMEs), industry consultants, and C-level executives of major companies, are conducted to obtain critical qualitative and quantitative information pertaining to the market, as well as to assess the prospects for market growth during the forecast period. Detailed information on these primary respondents is mentioned below.
Primary Source
Service Side Subject Matter Experts, Top Management, and CXOs
Technical Persons of Organizations Operating in the Market
Marketing and Business Development Managers, VPs, and Marketing Directors
Various Partner Consultants from the Demand and Supply Sides
PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
Respondents
Data Points Received
Manufacturer and Distributors
· Market Size
· Top of the Mind Key Market Players
· Direct Competitors
· Company Market Shares
· Growth Rate (%)
· Market Trends and Prominent Market Drivers
· Major Products
· Product Cost
· Commercial Availability
· Regional Scenario (America, Europe, APAC & Middle East, Africa)
· Data Protection Policies and Other Regulatory Norms
· Upcoming Products
End Users
· Adoption of New Technology
· Acceptance Ratio
· Cost of Bariatric Surgery Devices
· Commonly Used Bariatric Surgery Devices
BREAKDOWN OF PRIMARY RESPONDENTS
FORECASTING TECHNIQUES
We at MRFR follow an extensive process for arriving at market estimations, which involves the use of multiple forecasting techniques, as mentioned below.
Forecasting Techniques
Description
Qualitative and Quantitative Analysis
A combination of qualitative approach, i.e., primary interviews with industry experts to understand the interviewees’ opinions and judgments, more commonly known as the Delphi method, and quantitative analysis to forecast future data based on historical and current data.
Weighted Average Approach
Via this approach, future data is calculated based on the mean of the past data under the assumption that some factors affecting the market in the past will continue to have a similar impact in the future.
Drift Method
This approach is used to vary the forecast, which increases or decreases in market factor over time, depending on various parameters affecting the change in the trends of the market.
Time Series Methods
The integration of several time series methods such as moving average, moving weighted average, linear prediction, and trend estimation is applied while determining the year-on-year growth rate and the compound annual growth rate of the market being studied.
Causal/Econometric Forecasting Methods
Various economic factors such as inflation rate, fiscal policies, changes in government regulations, taxes, labor costs, and interest rates are taken into consideration while determining the current market size and predicting the future market growth rate.
Judgmental Methods
This involves the collection of intuitive judgment, opinions, and probability estimates from industry experts in the case of new or upcoming markets/technologies for which no prior data is available.
Regression Analysis
This type of statistical modeling is carried out for predicting and forecasting dependent and independent variables that will directly or indirectly impact the market.
Probabilistic Forecasting
This forecasting method is carried out to assign a probability to every possible outcome ranging from the least optimistic to highly optimistic, which helps in gauging the market under stable conditions.
PESTLE Analysis
Political, economic, social, technological, legal, and environmental factors are taken into consideration while deriving the fluctuations in the growth rate of the market.
Porter’s Five Forces Analysis
By understanding the supplier-side and demand-side factors, the current market scenario can be estimated, and future market scenarios predicted, which aid in deriving the growth rate of the market.
RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
Understanding and penetrating the market in terms of valuation is a crucial task in the process of business research. This again becomes significantly important while investing and choosing business opportunities. In this regard, we at MRFR performs two ways market sizing approach simultaneously, namely top-down and bottom-up approaches. In this step, we place different data points, numeric attributes, information, and industry trends at an appropriate space to deduce the estimates & forecast values over the coming years. We use different mathematical models to estimate the market sizes of different economies and segments. Each of which is further summed up to define the total market.
We at MRFR own a proprietary statistical tool for market estimations, which helps us to comprehend market size estimates & forecasts for different markets and industries.
bottom-up and top-down approaches
MRFR Analysis Overview
BOTTOM-UP APPROACH
In the bottom-up approach, the revenue of key companies and their shares in the market are assessed to deduce the market size. More than 20 key players operating in the global bariatric surgery devices market are studied. The segmental revenue of each player is analyzed, and the size for the global bariatric surgery devices market is extracted from the segmental/product/service revenue with the help of secondary and primary research. The extracted size for the market is then validated with industry experts and partner consultants. This derived market size contributes to around 65% to 70% of the total global market share in terms of revenue for the bariatric surgery devices market. Using the data triangulation method, the overall global market size is estimated.
1.6.2 TOP-DOWN APPROACH
The overall market size is then used in the top-down procedure to estimate the size of the other sub-markets with the help of percentage splits of the market segments from secondary and primary research. The demand-side analysis is conducted, in which the expenditure of significant industry players in each region is studied. The end-users considered in the scope of this research study contributes around 70% of the total spent in the bariatric surgery devices market.
The countries considered in the scope of the bariatric surgery devices market are the US, Canada, the UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Singapore, Malaysia, Indonesia, South Africa, and others.
The figure below depicts the process of market estimation using independent tools employed by our analysts to arrive at the sizing of the market.
MRFR Analysis Overview
As a part of the market engineering, both top-down and bottom-up approaches are utilized along with data triangulation models to derive and verify the market sizes and forecast over the coming years.
DATA TRIANGULATION
After arriving at the overall market sizes, the total market is divided into several segments and sub-segments. Again, the market breakdown and data triangulation procedures are implemented, wherever applicable, to complete the overall market engineering process and gather the exact statistics for all segments and sub-segments. The data is triangulated by studying various factors and trends from the demand and supply sides. Along with this, the market size is validated using the top-down and bottom-up approaches.
VALIDATION
Validation is the most crucial stage of the report making the process. Validation via an intricately designed feedback process helps us finalize the sizing estimates and forecast for the final collation. Extensive primary research is performed to verify the information. This includes telephonic and personal interviews, e-mails, feedback forms, questionnaires, and polling options/answers with a group of relevant industry participants. Validation helps to duly check the authenticity of the key industry trends, market dynamics, company market share, different business models, and conclusions.
Base Year
2018
Historical Period
2016 – 2018
Forecast Period
2018 – 2025
Primary Interviews
150+
Historical data (2016–2018) and forecast period (2018–2025)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMichael Porter’s five forces model gives a framework of the influence of five forces on the global influenza vaccines market. Strategic business managers, trying to create an edge over competing firms in the global influenza vaccines market, can utilize this model to comprehend better the industry connection in which the firm operates. The components of each of the forces and the degree or impact of each component in the context of the global influenza vaccines industry have been broken down and analyzed below.
Bargaining Power of Suppliers
The bargaining power of suppliers in the influenza vaccines market is low. In this market, the suppliers are the raw material manufacturers of vaccines. The market has the presence of many local and international companies that supply raw material for influenza vaccine. The switching cost of these suppliers is low as the raw material prices in this market are very competitive. Furthermore, increasing demand from research institutes and entry of multinational pharmaceutical companies in the market is further expected to keep the bargaining power of suppliers low. Moreover, presence of large number of suppliers would cater to the needs of the customers which will lead to the intense competition between the existing suppliers which thereby keep the bargaining power of suppliers low.
BARGAINING Power of Buyers
The bargaining power of buyers is moderate in the global influenza vaccines market. The number of buyers in the market is rising due to high prevalence of the disease and awareness of influenza. Besides, the pricing factor also plays a vital role in the bargaining power of buyers in the market as some buyers are price and brand sensitive and might prefer particular products from certain companies, thereby moderately affecting their bargaining power in the market.
Threat of New Entrants
The threat of new entrants is moderate in the global influenza vaccines market. Any manufacturing company trying to enter the market is required to accept or abide by the mandatory regulatory standards. However, the budget required for research and development of the influenza vaccine is high as compared to the other industries. Moreover, if a company desires to survive in the market, it must introduce innovative vaccines for prevention of influenza, and product innovation requires a large amount of investment as well as time. Also, there are very strict government regulations which a company must follow in the market. However, the presence of huge opportunities in the market has increased the threat of new entrants to the market.
Threat of Substitutes
The threat of substitutes in the global influenza vaccines market is low. Any threat from a close substitute product is measured to have a high impact on the market. The threat of substitutes arises when the buyers or the customers in the market can accomplish the end-result using other similar products. Although there is a low number of replacements or the presence of alternative products in the market, which eliminates the threat of substitutes.
Intensity of Rivalry
The degree of competition in the global influenza vaccines market is high. The moderate degree of product differentiation among existing players increases the intensity of rivalry in the market. Companies involved in the influenza vaccines market are trying to develop cost-effective products to make product differentiation. To overcome the competition, players are engaged in developing a process to lower their manufacturing costs. Moreover, the players are also developing advanced techniques for differentiating their products from their rivals, which encourages competition to gain maximum market share.
Market estimates by geography (2025)
InsightAmericas leads with $3.75B by 2025.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2016 | 2018 | 2025 | CAGR | SHARE |
|---|---|---|---|---|---|
| Middle East and Africa | $227.50M | $314.30M | $371.80M | 5.6% | 5% |
| Americas | $2.04B | $2.88B | $3.75B | 7.0% | 48% |
| Asia Pacific | $727.40M | $972.60M | $1.27B | 6.4% | 16% |
| Europe | $1.39B | $1.94B | $2.43B | 6.4% | 31% |
| Total | $4.38B | $6.10B | $7.83B | 6.7% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$7.83B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Seasonal | $6.91B | 6.7% | 89% |
| Zoonotic | $920.70M | 6.7% | 89% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Influenza Vaccines Market covering market dynamics, competitive landscape, and strategic outlook.
The Influenza Vaccines Market market is projected to reach $7.83B by 2025, growing at 6.7% CAGR. The Seasonal segment holds the largest share.
Influenza is an infection of the upper airway caused by an influenza virus, which is commonly known as flu. The most common symptoms include high fever, sore throat, headache, coughing, and sneezing. Influenza spreads across the world in seasonal outbreaks. Influenza viruses are one of the major infectious disease threats to the human population owing to both the health impact of annual influenza and the tremendous global consequences of influenza pandemics. Seasonal influenza alone causes 250,000 to 500,000 deaths and 3 to 5 million cases of severe illness worldwide each year.
Among humans, the annual epidemic influenza illness is caused by two types of influenza viruses, namely, influenza A and influenza B. Influenza viruses undergo constant genetic change, which has a substantial impact on induced immunity, and the changes are also considered for vaccine composition. Currently available seasonal influenza vaccines are either trivalent or quadrivalent in composition.
The rising prevalence of influenza, increasing public and private initiatives for influenza vaccine research and development, growing awareness about influenza vaccine, and increasing product launches and approvals are driving the global influenza vaccines market. However, stringent regulatory policies and product recalls are expected to hamper the growth of this market.
Influenza is a highly infectious respiratory disease. According to the Centers for Disease Control and Prevention (CDC), influenza has resulted in between 9.3 million to 49.0 million cases of illnesses. It also estimated between 140,000 and 960,000 hospitalizations and between 12,000 and 79,000 deaths annually since 2010 in the US alone. Influenza is an important cause of outpatient medical visits and hospitalizations among children and old age adults. In a population-based retrospective cohort study, hospitalization rates for children aged less than 5 years with acute respiratory illness (ARI) or laboratory-confirmed influenza (LCI)-associated fever averaged 7.7 per 100,000. Furthermore, people aged 65 years and above accounted for approximately 58% of reported influenza-associated hospitalizations in 2018.
As per the National Influenza Centers (NICs) Report 2018, 69,007 people were diagnosed with influenza viruses, out of which 67,733 were diagnosed with the influenza A virus and 1,274 with the influenza B virus, respectively. It is estimated that 30% of the burden of communicable diseases in Europe is due to influenza. Up to 50 million people each year are estimated to have symptomatic influenza in EU (European Union)/EEA (the European Economic Area (EEA) countries, and therefore between 15,000 and 70,000 people are estimated to die from influenza-associated causes. According to the World Health Organization Report 2017, the influenza virus is continuously growing in the South-East Asia region. Globally, 91% of the population were diagnosed with the influenza A virus, out of which 9% were associated with the influenza B virus. The worst flu outbreak on record occurred in 2015, during which 7,10,000 US citizens were hospitalized due to swine flu with a death toll of 56,000 citizens. This surge in influenza epidemics rises the demand for influenza vaccines, thereby contributing to the growth of the market.
The number of clinical trials for influenza vaccine continues to grow worldwide. According to the Clinical Trials Database, around 112 clinical trials for influenza vaccine were reported in the UK in 2018. Overall there has been a net increase in the number of new and ongoing influenza vaccine clinical trials, with many new trials and an increasing amount of influenza vaccine trials. Major companies are focused on evaluating their vaccines and improving the success rates of their products. For instance, prominent players, namely, GlaxoSmithKline and Sanofi, have clinical trial candidates for influenza vaccine in Phase II & III.
The scientists of NIAID Vaccine Research Center have initiated Phase 1/2 studies of a universal flu vaccine strategy that includes an investigational DNA-based vaccine (called a DNA “prime”) followed by a licensed seasonal influenza vaccine (“boost”) to improve the potency and durability of seasonal influenza vaccines. In May 2018, NIAID launched a Phase 2 clinical trial of a universal influenza vaccine called M-001. The vaccine, which was developed and produced by BiondVax Pharmaceuticals based in Ness Ziona, Israel, contains antigenic peptide sequences shared among many different influenza strains.
Thus, increase in number of clinical trials is expected to result in subsequent launch of new products in the market in the upcoming years and thereby is expected to boost the market growth.
The manufacturing of influenza vaccines follows crucial steps and processes. These processes differ on the basis of manufacturer, country regulation, adoption rate of the country, and the pricing of vaccines in different regions. In some economies such as Japan and China, regulatory processes are given utmost importance. The healthcare regulatory authorities of these countries employ strict policies and processes for the approval of products. The progress in vaccine regulation globally includes shifts towards strictly defined procedures for vaccine consistency, reliance on Good Manufacturing Practices (GMPs), and the final product testing. Also, vaccine pharmacovigilance and impact surveillance studies must be carried out. Surveillance systems exist at national and international levels to ensure effective monitoring and prompt actions in response to adverse event following immunization (AEFI).
Therefore, the focus of regulatory authorities on the approval of vaccines is increasing, and this may act as a factor that would curb the growth of the market in the near future.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 109 companies operating in the Influenza Vaccines Market market, including revenue, employee count, and market positioning where available.
Showing 109 of 109 companies
Serum Institute of India Pvt. Ltd
Company Headquarters: Pune, Maharashtra, India Founded: 1966 Workforce: ~ 1001-5000 Company Working: Serum Institute of India Pvt. Ltd is a major player in the global vaccines market. The company manufactures more than 1.3 billion doses per year and is the largest manufacturer in the world, by volume. It is also India’s largest biotechnology company. It is estimated that about 65% of the children in the world receive at least one vaccine manufactured by the Serum Institute. It focuses on manufacturing life-saving vaccines for chronic diseases such as Diphtheria, Tetanus, Pertussis, Hib, BCG, r-Hepatitis B, Measles, Mumps, and Rubella. It operates through business segments, namely, bacterial vaccines, polysaccharide conjugate vaccines, influenza vaccines, viral vaccines, anti-sera, uro-oncology, recombinant products, and combination vaccines. It has operations in key five continents (Africa, America, Asia, Australia/Oceania, and Europe) and provides its products in more than 170 countries. It generates maximum revenue from the sales of vaccines.
Mitsubishi Tanabe Pharma
Company Headquarters: Japan Founded: 1678 Workforce: ~ 69,784 Revenue: USD 34.64 Billion Company Working: Mitsubishi Tanabe Pharma Corp (Mitsubishi Tanabe), a subsidiary of Mitsubishi Chemical Holdings Corp, identifies, develops, manufactures, procures, and commercializes ethical drugs and over the counter (OTC) pharmaceutical products. The company develops ethical drugs for autoimmune disease, diabetes, kidney diseases, central nervous system (CNS) disorders, and others. It also develops vaccines for preventing various infectious diseases. Mitsubishi Tanabe also offers major products for skin conditions and digestive medicines. The company markets its products to wholesalers, hospitals, clinics, and drugstores. It has subsidiaries in Asia, Europe, and North America. Mitsubishi Tanabe is headquartered in Osaka, Japan.
Hualan Biological Engineering Inc.
Company Headquarters: China Founded: 1992 Workforce: ~ 2,927 Company Working: Hualan is a pharmaceutical firm specializing in the production of direct or indirect contact injection pharmaceutical packaging materials. Hualan Biological Engineering Inc. (Hualan Bio) is a key National high-tech biopharmaceutical company in China engaging in the research, development, production, and commercialization of plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics. Hualan Bio was the first company whose plasma products gained GMP certificate in China, the first listed company of plasma products, the first H1N1 Influenza Vaccine manufacturer in the whole world, the first influenza vaccine manufacturer passing WHO-PQ in China. Passing "ISO9000" (quality), "ISO14000" (environment) and "GBT28000" (occupational health) management system certification. As a major manufacturer for the plasma products and vaccines designated by national authorities, Hualan Bio is the largest manufacturer and provider for both plasma products and influenza vaccines in Asia. Hualan Bio is the leading company which has integrated the innovative R & D activities, state-of the-art technologies, scientific management styles and high standard quality control and assurance systems in China. The company has been undertaking research projects from national, provincial, and municipal organizations. In 2010, Hualan Bio formed a strategic alliance with the Chinese Academy of Sciences (CAS) and collaborates with several institutes for the discovery of innovative biologics. Recently, the R & D center at Hualan Bio was recognized as one of the National High-tech Center in China, which built the solid foundation for the development of novel products and future growth.
Seqirus
Company Headquarters: Maidenhead, UK Founded: 2015 Workforce: ~1001-5000 Company Working: Seqirus was established in July 2015, following the Commonwealth Serum Laboratories (CSL)’s acquisition of the Novartis influenza vaccines business, and subsequent integration with bioCSL. Seqirus is one of the world’s largest influenza vaccine companies and is one of the major partners in the prevention and control of influenza globally. The company is a reliable supplier of influenza vaccine for northern and southern hemisphere markets. Each Seqirus facility provides pandemic preparedness to their host countries as well as other countries in their respective regions. Seqirus utilizes both egg-based and cell-culture based manufacturing technologies as well as a proprietary adjuvant for vaccine production. The company has leading R&D capabilities, a broad and differentiated product portfolio, and commercial operations in more than 20 countries. In Australia and the Asia-Pacific region, Seqirus is a leading provider of in-licensed vaccines and specialty pharmaceuticals.
AstraZeneca
Company Headquarters: Cambridge, UK Founded: 1999 Workforce: 83,100 Company Working: AstraZeneca is a leading biopharmaceutical company. It focuses on developing and commercializing prescribed medicines. It has three main therapy areas, namely, cardiovascular, and metabolic disease (CVMD), oncology, and respiratory. It is also active in areas such as neuroscience autoimmunity and infection. It has more than 164 projects in its pipeline, nine new molecular entities in its late-stage pipeline, and one new molecular entity approval in the last quarter of 2019. Its product portfolio includes medications in the field of oncology, cardiovascular, renal & metabolism, and respiratory diseases, among others. Geographically the company operates in more than 100 countries by offering its healthcare products to millions of people across the globe.
SANOFI
Sanofi is a UK-based global life sciences company which was incorporated in the year 2004. Sanofi is headquartered in Paris having the employee strength of more than 110,000 spread in more than 100 countries and have industrial sites in more than 40 countries. The company is committed to improve the access to healthcare and support the people to whom it serves throughout the continuum of care. Further, the company has its offerings into healthcare solutions, human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions, and consumer healthcare. Sanofi CEPiA is a subsidiary business unit of Sanofi that produces articaine hydrochloride in API form. It is a market leader in producing articaine hydrochloride. The company manufactures articaine hydrochloride in its high capacity FDA approved workshop. Sanofi’s Ankleshwar production plant has an export sales of Rs. 54,900 lakhs that is around 27% of their total sales in India in 2015 . Their healthcare solutions are available in more than 170 countries across the world and now Sanofi is focussing on increasing its presence in emerging countries. Their industrial network, know-how and employees deliver a wide range of health solutions to millions of individuals with high quality and safety. Some of the top competitors of Sanofi are Pfizer Inc., Merck & Co., Inc. GlaxoSmithKline Plc., Septodont, Dentsply Sirona, and Pierrel S.p.A., among others.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Influenza Vaccines Market